It has experienced a hiccup, but the company is still on the right path. That’s the opinion of Roth MKM analyst Bill Kirk on ...

Canopy Growth Corporation ... We saw strong growth in Poland and Germany, which was partially offset by the decline in sales ...

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Walt Disney Company. Read Investing.com (Jesse Cohen)'s latest article on ...

Canopy Growth's revenue and EBITDA have been disappointing, and analysts' projections for FY25 and FY26 remain weak. Read why ...

Detailed price information for Canopy Growth Corp (CGC-Q) from The Globe and Mail including charting and trades.

Bank of America (BAC) analyst Justin Post maintained his Neutral rating on the stock, raising his near-term estimates for ...

I would like to welcome you to Canopy Group's ... We saw strong growth in Poland and Germany, which was partially offset by the decline in sales in our Australian medical cannabis business, driven by ...

The sustainability of the stock's immediate price movement ... trend for Canopy Growth: unfavorable. While the magnitude and direction of estimate revisions could change following the company's ...

Canopy saw a significant decline in Canadian adult-use cannabis, where revenue fell 24% to C$18.4 million. This offset the 16% gain from Canadian medical cannabis which reached C$18.7 million, and ...

Canopy Growth reported 9% a year-over-year decrease in net revenue to CA$63 million ($45.4 million). Adjusted EBITDA loss was ...

The company saw a huge decline in Canadian adult-use cannabis, with revenues down 24% at C$18.4 million from that category, offsetting the 16% gain from Canadian medical cannabis which reached C$18.7 ...